奥利司他对比二甲双胍降低超体质量或肥胖患者体质量疗效和安全性的Meta分析(4)
[ 3 ] CHO LW，KILPATRICK ES，KEEVIL BG，et al. Effect of metformin，orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome[J]. Clin Endocrinol，2009，70(2)：233- 237.
[ 4 ] GHANDI S，AFLATOONIAN A，TABIBNEJAD N，et al. The effects of metformin or orlistat on obese women with polycystic ovary syndrome：a prospective randomized open-label study[J]. J Assist Reprod Genet，2011，28(7)：591-596.
, 百拇医药
[ 5 ] JAYAGOPAL V，KILPATRICK ES，HOLDING S，et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome[J]. J Clin Endocrinol Metab，2005，90(2)：729-733.
[ 6 ] KUMAR P，ARORA S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates[J]. J Hum Reprod Sci，2014，7(4)：255-261.
[ 7 ] 涂傳发，沈飞霞.胃肠道脂肪酶抑制剂联合双胍类降糖药对肥胖伴多囊不孕女性血清雌激素水平的影响[J].中国生化药物杂志，2016，36(8)：61-64.
, 百拇医药
[ 8 ] METWALLY M，AMER S，LI TC，et al. An RCT of metformin versus orlistat for the management of obese anovulatory women[J]. Hum Reprod，2009，24(4)：966-975.
[ 9 ] GOKCEL A，GUMURDULU Y，KARAKOSE H，et al. Evaluation of the safety and efficacy of sibutramine，orlistat and metformin in the treatment of obesity[J]. Diabetes Obes Metab，2002，4(1)：49-55.
[10] 朱于坚.肥胖2型糖尿病奥利司他治疗效果的初步观察[J]. 海峡药学，2016，28(6)：162-163.
, http://www.100md.com
[11] KARGULEWICZ A，SZULINSKA M，KUJAWSKA- LUCZAK M，et al. Improvement of serum adiponectin and leptin concentrations：effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial[J]. Eur Rev Med Pharmacol Sci，2016，20(18)：3868-3876.
[12] BRAY GA. Medical treatment of obesity：the past，the present and the future[J]. Best Pract Res Clin Gastroenterol，2014，28(4)：665-684.
, http://www.100md.com [13] ALQAHTANI S，QOSA H，PRIMEAUX B，et al. Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition[J]. Eur J Pharmacol，2015，762(3)：263-269.
[14] SAHEBKAR A，SIMENTAL-MENDIA LE，REINER Z，et al. Effect of orlistat on plasma lipids and body weight：a systematic review and meta-analysis of 33 randomized controlled trials[J]. Pharmacol Res，2017.DOI：10.1016/j.phrs.2017.05.022.
[15] LEBLANC ES，O’CONNOR E，WHITLOCK EP，et al. Effectiveness of primary care-relevant treatments for obesity in adults：a systematic evidence review for the U.S. Preventive Services Task Force[J]. Ann Intern Med，2011，155(7)：434-447.
[16] DEROSA G，MAFFIOLI P，SAHEBKAR A. Improvement of plasma adiponectin，leptin and C-reactive protein concentrations by orlistat：a systematic review and meta-analysis[J]. Br J Clin Pharmacol，2016，81(5)：819- 834., 百拇医药(刘永健 李凌鸥 程菲菲 刘玉婷 魏洁 刘东方)
[ 4 ] GHANDI S，AFLATOONIAN A，TABIBNEJAD N，et al. The effects of metformin or orlistat on obese women with polycystic ovary syndrome：a prospective randomized open-label study[J]. J Assist Reprod Genet，2011，28(7)：591-596.
, 百拇医药
[ 5 ] JAYAGOPAL V，KILPATRICK ES，HOLDING S，et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome[J]. J Clin Endocrinol Metab，2005，90(2)：729-733.
[ 6 ] KUMAR P，ARORA S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates[J]. J Hum Reprod Sci，2014，7(4)：255-261.
[ 7 ] 涂傳发，沈飞霞.胃肠道脂肪酶抑制剂联合双胍类降糖药对肥胖伴多囊不孕女性血清雌激素水平的影响[J].中国生化药物杂志，2016，36(8)：61-64.
, 百拇医药
[ 8 ] METWALLY M，AMER S，LI TC，et al. An RCT of metformin versus orlistat for the management of obese anovulatory women[J]. Hum Reprod，2009，24(4)：966-975.
[ 9 ] GOKCEL A，GUMURDULU Y，KARAKOSE H，et al. Evaluation of the safety and efficacy of sibutramine，orlistat and metformin in the treatment of obesity[J]. Diabetes Obes Metab，2002，4(1)：49-55.
[10] 朱于坚.肥胖2型糖尿病奥利司他治疗效果的初步观察[J]. 海峡药学，2016，28(6)：162-163.
, http://www.100md.com
[11] KARGULEWICZ A，SZULINSKA M，KUJAWSKA- LUCZAK M，et al. Improvement of serum adiponectin and leptin concentrations：effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial[J]. Eur Rev Med Pharmacol Sci，2016，20(18)：3868-3876.
[12] BRAY GA. Medical treatment of obesity：the past，the present and the future[J]. Best Pract Res Clin Gastroenterol，2014，28(4)：665-684.
, http://www.100md.com [13] ALQAHTANI S，QOSA H，PRIMEAUX B，et al. Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition[J]. Eur J Pharmacol，2015，762(3)：263-269.
[14] SAHEBKAR A，SIMENTAL-MENDIA LE，REINER Z，et al. Effect of orlistat on plasma lipids and body weight：a systematic review and meta-analysis of 33 randomized controlled trials[J]. Pharmacol Res，2017.DOI：10.1016/j.phrs.2017.05.022.
[15] LEBLANC ES，O’CONNOR E，WHITLOCK EP，et al. Effectiveness of primary care-relevant treatments for obesity in adults：a systematic evidence review for the U.S. Preventive Services Task Force[J]. Ann Intern Med，2011，155(7)：434-447.
[16] DEROSA G，MAFFIOLI P，SAHEBKAR A. Improvement of plasma adiponectin，leptin and C-reactive protein concentrations by orlistat：a systematic review and meta-analysis[J]. Br J Clin Pharmacol，2016，81(5)：819- 834., 百拇医药(刘永健 李凌鸥 程菲菲 刘玉婷 魏洁 刘东方)